Drugs / Furosemide
Furosemide
also known as
Lasix · frusemide · Furoscix · CLS006 · Lasix (Furosemide) · Lasix ONYU · SQINFurosemide · Furosemide Injection · +8 more
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | FUROSCIX | — | 2024-08-09 – 2026-07-23 | fda.gov ↗ |
| Approved | EU (EMA) | Bopediat | — | 2026-05-29 | europa.eu ↗ |
| Label expansions (2) | US (FDA) | LASIX | — | 1981-02-05 – 2007-12-07 | fda.gov ↗ |
| Approved | US (FDA) | LASIX | — | 1966-07-01 | fda.gov ↗ |
Trials 178 · started per year
today
US approved 1966
EU approved 2026
1
1
1
3
1
6
2
2
5
4
6
4
5
5
5
15
14
11
9
6
12
12
4
13
12
7
10
19651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT06821594 | Apr → Aug 2025 overdue | benign neoplasm of skin | Jinnah Postgraduate Medical Centre | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT05365451 | Apr 2022 → Jul 2023 | — | Washington State University | Completed | No outcome recorded |
| Phase 0 | NCT05098366 | May 2021 → Dec 2023 | — | Connecticut Children's Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT03837470 | May 2019 → Feb 2020 | diastolic heart failure | Adhish Agarwal | Completed | No outcome recorded |
| Phase 0 | NCT03772262 | Apr → Nov 2018 | — | Washington State University | Completed | No outcome recorded |
| Phase 0 | NCT02802696 | Jun 2016 → Mar 2017 | — | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 0 | NCT03946891 | Jun 2016 → Jun 2023 | pulmonary immaturity | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 136 trials | ||||||
| Phase 1 | NCT07431866 | Mar → Jun 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07269496 | Feb → Mar 2026 | — | SQ Innovation, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT07073157 | Jul → Aug 2025 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06504862 | Aug → Oct 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06491550 | Jul 2024 → Jun 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06167707 | Apr → Jun 2024 | heart failure | scPharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05768360 | Apr → Jun 2023 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05981365 | Apr → Oct 2023 | sickle cell disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04850638 | Jun → Sep 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04846816 | May → Aug 2021 | heart failure | SQ Innovation, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04763226 | Apr 2021 → Feb 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04590937 | Oct 2020 → Jan 2021 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05105009 | Mar 2020 → Oct 2023 | chronic renal failure syndrome | Instituto Nacional de Cardiologia Ignacio Chavez | Completed | No outcome recorded |
| Phase 1 | NCT04233437 | Feb → May 2020 | stroke disorder | Moleac Pte Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04161482 | Dec 2019 → Jun 2020 | — | scPharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04481789 | Oct → Dec 2018 | — | Shionogi | Completed | No outcome recorded |
| Phase 1 | NCT03801759 | Jul → Sep 2018 | — | Akebia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT07173738 | Jun → Sep 2018 | pulmonary arterial hypertension | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT03307252 | Oct 2017 → May 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03103568 | Mar → Jun 2017 | — | Swedish Orphan Biovitrum | Completed | No outcome recorded |
| Phase 1 | NCT03010475 | Jan → Jun 2017 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02877095 | Dec 2016 → Nov 2017 | heart failure | Adrian Hernandez | Completed | No outcome recorded |
| Phase 1 | NCT02854527 | Aug → Nov 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01851980 | Apr 2016 → Apr 2017 | — | McGill University | Unknown | No outcome recorded |
| Phase 1 | NCT02574845 | Oct → Dec 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02881866 | Oct 2015 → Mar 2016 | — | Oxford Brookes University | Completed | No outcome recorded |
| Phase 1 | NCT02546583 | Aug 2015 → Jan 2020 | heart failure | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT02231931 | Sep 2014 → Jan 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02028689 | Oct → Nov 2013 | — | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01887379 | Jun → Aug 2013 | — | LTS Lohmann Therapie-Systeme AG | Completed | No outcome recorded |
| Phase 1 | NCT01724788 | Nov 2012 → Jan 2013 | kidney failure | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01438359 | Jul → Sep 2011 | — | Vifor Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01611415 | Jul → Oct 2011 | — | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 1 | NCT01062776 | Oct 2009 → May 2010 | — | Sodertalje Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00671424 | Mar → May 2008 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00261937 | Dec 2005 → Apr 2006 | bronchiolitis | Bnai Zion Medical Center | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT06024889 | Sep 2023 → Feb 2024 | heart failure | Johannes Grand | Completed | No outcome recorded |
| Phase 1/2 | NCT04384653 | Oct 2020 → Jun 2021 | heart failure | SQ Innovation, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02721511 | May 2016 → Mar 2017 | heart failure | Todd M Koelling, MD | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02350725 | Dec 2014 → Jun 2015 | heart failure | scPharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02524054 | Nov 2014 → Nov 2016 | — | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01440764 | Sep 2011 → Apr 2016 | — | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00982423 | Jul 2009 → Jul 2014 | heart failure, impaired renal function disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 225 trials | ||||||
| Phase 2 | NCT07648251 | Jun → Dec 2026 expected | severe pre-eclampsia | Universidad Nacional Autonoma de Honduras | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07307131 | Sep 2024 → Mar 2025 | common wart, human papilloma virus infection | Benha University | Completed | No outcome recorded |
| Phase 2 | NCT06326112 | May 2024 → Mar 2025 | acute respiratory distress syndrome, critical illness polyneuropathy, infectious disease with sepsis | Unity Health Toronto | Unknown | No outcome recorded |
| Phase 2 | NCT05528588 | Jun 2023 → Apr 2024 | heart failure | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT05779943 | Apr 2023 → Mar 2024 overdue | prostate adenocarcinoma | Emory University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04919564 | May → Dec 2021 | chronic kidney disease, heart disorder | National Cardiovascular Center Harapan Kita Hospital Indonesia | Completed | No outcome recorded |
| Phase 2 | NCT04593823 | May 2021 → Apr 2022 | heart failure | scPharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04622709 | Oct 2020 → Jun 2021 | end stage renal failure | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT03684772 | Oct 2018 → Sep 2019 | actinic keratosis | Maruho Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03556761 | Jun 2018 → Dec 2019 | hypertension, pregnancy-induced | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT03170219 | Apr → Sep 2018 | heart failure | Adrian Hernandez | Terminated | No outcome recorded |
| Phase 2 | NCT03259165 | Dec 2017 → Dec 2021 | heart failure, pulmonary edema | Indiana University | Terminated | No outcome recorded |
| Phase 2 | NCT03362515 | Dec 2017 → Apr 2022 | nasal cavity polyp | Thomas Jefferson University | Terminated | No outcome recorded |
| Phase 2 | NCT03364842 | Nov → Dec 2017 | lung disorder | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT03334240 | Oct 2017 → Oct 2018 | anogenital human papillomavirus infection | Maruho Co., Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT04393493 | Jul 2017 → Apr 2020 | cardio-renal syndrome | Hospital Civil de Guadalajara | Completed | No outcome recorded |
| Phase 2 | NCT02804035 | Jul → Aug 2016 | heart failure | scPharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02527798 | Nov 2015 → Oct 2019 | bronchopulmonary dysplasia | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT02450773 | Aug 2015 → May 2022 | hypertensive disorder | Indiana University | Withdrawn | No outcome recorded |
| Phase 2 | NCT02333643 | Jan → Aug 2015 | benign neoplasm of skin | Maruho Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02821377 | Dec 2013 → Dec 2015 | cirrhosis of liver | University of Palermo | Completed | No outcome recorded |
| Phase 2 | NCT02469597 | Oct 2013 → Apr 2016 | bronchiolitis | Northwell Health | Completed | No outcome recorded |
| Phase 2 | NCT01407848 | Jan 2012 → Jul 2015 | persistent tachypnoe of infancy, usual | University of Cologne | Completed | No outcome recorded |
| Phase 2 | NCT01125514 | May 2010 → Aug 2011 | heart failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00624650 | Feb 2008 → Jan 2011 | acute lung injury | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT06252454 | Feb → Dec 2024 | — | University Hospital Hradec Kralove | Unknown | No outcome recorded |
| Phase 2/3 | NCT05652322 | Dec 2022 → Dec 2023 | heart failure | Jan Kochanowski University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT04588792 | Apr 2021 → Feb 2023 | COVID-19, respiratory failure | Dr. John Muscedere | Terminated | No outcome recorded |
| Phase 2/3 | NCT03359161 | Apr 2018 → Jan 2019 | heart failure | Steward St. Elizabeth's Medical Center of Boston, Inc. | Terminated | No outcome recorded |
| Phase 2/3 | NCT02579057 | Feb 2016 → Jun 2017 | congestive heart failure | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2/3 | NCT02329834 | Apr → Oct 2015 | heart failure | scPharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 326 trials | ||||||
| Phase 3 | NCT07018297 | Aug 2026 → Aug 2028 expected | heart failure | University of Texas Southwestern Medical Center | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06941415 | Jun 2026 → Mar 2029 expected | cirrhosis of liver | Stacy Johnson | Recruiting | No outcome recorded |
| Phase 3 | NCT07008365 | Mar 2025 → Nov 2026 expected | cardio-renal syndrome, congestive heart failure | Aragon Health Research Institute (IISAragon) | Recruiting | No outcome recorded |
| Phase 3 | NCT06407401 | Dec 2024 → Apr 2028 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, musculoskeletal system disorder | European Organisation for Research and Treatment of Cancer - EORTC | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05916963 | Jan 2024 → Apr 2026 overdue | urolithiasis | University Hospital, Tours | Recruiting | No outcome recorded |
| Phase 3 | NCT05620784 | Mar → Jun 2023 overdue | benign prostatic hyperplasia | Northwestern University | Recruiting | No outcome recorded |
| Phase 3 | NCT05769738 | Mar 2023 → Dec 2024 | chronic obstructive pulmonary disease | American University of Beirut Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT05962255 | Feb 2022 → Apr 2024 | heart failure | Wroclaw Medical University | Completed | No outcome recorded |
| Phase 3 | NCT04752475 | Oct 2021 → Apr 2022 | preeclampsia | Columbia University | Completed | No outcome recorded |
| Phase 3 | NCT04706910 | Jan 2021 → Dec 2027 expected | Lewy body dementia, Parkinson disease, brain neoplasm, congenital isolated hyperinsulinism +2 | University of Alberta | Recruiting | No outcome recorded |
| Phase 3 | NCT04615624 | Jan 2021 → Apr 2022 | preeclampsia | Melanie Maykin, MD | Completed | No outcome recorded |
| Phase 3 | NCT03458325 | Nov 2020 → Jun 2021 | heart failure | scPharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05270421 | Jul 2020 → Mar 2022 | nephrolithiasis, ureterolithiasis | Shiraz University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT03259620 | Oct 2017 → Aug 2018 | common wart | Maruho Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02971891 | Jan 2017 → Apr 2018 | common wart | Maruho Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02905760 | Dec 2016 → Nov 2018 | acute myocardial infarction | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 3 | NCT03208894 | Nov 2016 → May 2017 | persistent tachypnoe of infancy, usual | Armed Forces Hospital, Pakistan | Completed | No outcome recorded |
| Phase 3 | NCT02804282 | Jul → Nov 2016 | heart failure | scPharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02345681 | May 2015 → Apr 2019 | — | Nantes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02417883 | Apr 2015 → Apr 2016 | chronic kidney disease | Instituto Nacional de Cardiologia Ignacio Chavez | Unknown | No outcome recorded |
| Phase 3 | NCT01028170 | Nov 2009 → Jul 2011 | congestive heart failure, impaired renal function disease | Aspirus Heart and Vascular Institute-Research and Education | Completed | No outcome recorded |
| Phase 3 | NCT00702728 | Jun 2008 → Jun 2009 | acute tubulointerstitial nephritis | Centro Cardiologico Monzino | Unknown | No outcome recorded |
| Phase 3 | NCT00577135 | Feb 2008 → Jan 2010 | heart failure | Duke University | Completed | No outcome recorded |
| Phase 3 | NCT00618852 | Jan 2007 → Dec 2008 | lung disorder | The Hospital for Sick Children | Unknown | No outcome recorded |
| Phase 3 | NCT00298454 | Dec 2005 → Apr 2007 | kidney failure | Frisius Medisch Centrum | Terminated | No outcome recorded |
| Phase 3 | NCT00512811 | — | bronchiolitis | Baqiyatallah Medical Sciences University | Completed | No outcome recorded |
| Phase 433 trials | ||||||
| Phase 4 | NCT07577596 | Jun 2026 → Sep 2027 expected | heart failure | University of Aarhus | Recruiting | No outcome recorded |
| Phase 4 | NCT07167862 | Jun 2026 → Jun 2028 expected | preeclampsia | University of California, Irvine | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06979726 | Nov 2025 → Nov 2026 expected | heart failure | University of Florida | Recruiting | No outcome recorded |
| Phase 4 | NCT06094816 | Mar 2024 → Jan 2028 expected | — | University of Delaware | Recruiting | No outcome recorded |
| Phase 4 | NCT06229990 | Jan 2024 → Dec 2028 expected | acute kidney injury | Chiang Mai University | Recruiting | No outcome recorded |
| Phase 4 | NCT05898022 | Aug 2023 → Jul 2025 | bronchopulmonary dysplasia | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 4 | NCT05915286 | May 2023 → Feb 2025 | end stage renal failure | University of Alberta | Terminated | No outcome recorded |
| Phase 4 | NCT05171686 | Feb 2023 → Oct 2025 | chronic kidney disease, hypertensive disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT05158153 | Oct 2021 → Apr 2022 | acute hypotension, acute kidney injury | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 4 | NCT04192110 | Aug 2020 | chronic kidney disease | VA Office of Research and Development | Withdrawn | No outcome recorded |
| Phase 4 | NCT04343235 | May 2020 → Jun 2022 | hypertension, pregnancy-induced | Wright State University | Terminated | No outcome recorded |
| Phase 4 | NCT03731117 | Jul 2019 → Dec 2020 | acute kidney injury | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 4 | NCT03892148 | May 2019 → Jan 2023 | heart failure | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 4 | NCT02960412 | May 2017 → Mar 2018 | — | University of South Florida | Completed | No outcome recorded |
| Phase 4 | NCT02531581 | Dec 2015 → Apr 2020 | pulmonary embolism | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| Phase 4 | NCT02458157 | Oct 2015 → Jun 2017 | acute kidney injury | Nordsjaellands Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT02832973 | Sep 2015 → Dec 2017 | resistant hypertension | Sao Jose do Rio Preto Medical School | Completed | No outcome recorded |
| Phase 4 | NCT02539810 | Sep 2015 → Dec 2016 | renal artery atheroma, resistant hypertension | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 4 | NCT02351934 | Feb 2015 → Apr 2016 | large intestine disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT02643147 | Jan 2015 → Jan 2017 | heart failure | Fundación para la Investigación del Hospital Clínico de Valencia | Completed | No outcome recorded |
| Phase 4 | NCT02163655 | Jun → Nov 2014 | severe pre-eclampsia | Instituto Materno Infantil Prof. Fernando Figueira | Completed | No outcome recorded |
| Phase 4 | NCT01977430 | Nov 2013 → Mar 2015 | chronic kidney disease | Corporacion Parc Tauli | Unknown | No outcome recorded |
| Phase 4 | NCT04691687 | May 2012 → Dec 2017 | heart failure | New York Presbyterian Brooklyn Methodist Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01156220 | Jan → Jun 2012 | — | University Medical Center Hamburg-Eppendorf | Withdrawn | No outcome recorded |
| Phase 4 | NCT01441245 | Apr 2010 → Jun 2016 | heart failure | University of Siena | Completed | No outcome recorded |
| Phase 4 | NCT00535925 | Oct 2005 → Dec 2011 | diabetic kidney disease | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT00478543 | Sep 2005 → May 2008 | chronic kidney disease | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT00741663 | Apr 2005 → Sep 2008 | cirrhosis of liver | University of Padova | Completed | No outcome recorded |
| Phase 4 | NCT00200694 | Mar 2005 → Mar 2007 | proteinuria | Nantes University Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00664222 | Jan 2004 → Dec 2005 | heart failure | Tottori University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00652652 | Mar 2003 → Jan 2004 | congestive heart failure | Scios, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00306696 | Oct 2002 → Jan 2004 | diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00115726 | Sep 2000 → Feb 2006 | congestive heart failure, hypertensive disorder, hypotensive disorder | University of Calgary | Completed | No outcome recorded |
| Phase not applicable38 trials | ||||||
| — | NCT07550790 | Jul 2026 → Jun 2027 expected | heart failure, impaired renal function disease | Jin Joo Park | Recruiting | No outcome recorded |
| — | NCT07631780 | Jun 2026 → Dec 2027 expected | symptomatic heart failure | Nurgul Ablakimova | Not yet recruiting | No outcome recorded |
| — | NCT07348510 | Jan → Jul 2026 overdue | — | Cairo University | Recruiting | No outcome recorded |
| — | NCT07077772 | Jun 2025 → Oct 2027 expected | — | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| — | NCT07417969 | Jun 2025 → Sep 2026 expected | anuria | Jose J Zaragoza, MD MSc | Recruiting | No outcome recorded |
| — | NCT07336485 | Jan → Jul 2025 | nephrolithiasis | Ain Shams University | Completed | No outcome recorded |
| — | NCT06765031 | Nov 2024 → Mar 2026 overdue | acute kidney injury | Gulhane Training and Research Hospital | Recruiting | No outcome recorded |
| — | NCT07464249 | Apr → Sep 2024 | heart failure | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey | Completed | No outcome recorded |
| — | NCT05741372 | Sep 2023 → Dec 2024 | cirrhosis of liver | Boehringer Ingelheim | Completed | No outcome recorded |
| — | NCT05939193 | Jul 2023 → Jul 2024 | acute kidney injury | Peking University First Hospital | Completed | No outcome recorded |
| — | NCT05440851 | Apr 2023 → Mar 2027 expected | respiratory failure | University Health Network, Toronto | Recruiting | No outcome recorded |
| — | NCT06710600 | Sep 2022 → Apr 2024 | photosensitivity disease | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT06097923 | Nov 2021 → Dec 2022 | — | Seoul St. Mary's Hospital | Completed | No outcome recorded |
| — | NCT04170855 | Oct 2020 → Dec 2026 expected | cardio-renal syndrome | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Active not recruiting | No outcome recorded |
| — | NCT04235062 | Apr 2020 → Apr 2021 | heart failure | Momentum Research, Inc. | Completed | No outcome recorded |
| — | NCT05379257 | Jan 2020 → Dec 2022 | congestive heart failure | Hadassah Medical Organization | Unknown | No outcome recorded |
| — | NCT04182854 | Oct 2019 → Feb 2020 | antidepressant type abuse | Capital Medical University | Unknown | No outcome recorded |
| — | NCT07568886 | Apr 2019 → Apr 2023 | ovarian hyperstimulation syndrome | Al-Nahrain University | Completed | No outcome recorded |
| — | NCT03613779 | Apr 2018 → Dec 2019 | heart failure | Instituto Nacional de Cardiologia Ignacio Chavez | Completed | No outcome recorded |
| — | NCT03071536 | Nov 2016 → May 2026 overdue | impaired renal function disease | King Chulalongkorn Memorial Hospital | Recruiting | No outcome recorded |
| — | NCT02765009 | Jun 2016 → Jul 2019 | — | Central Hospital, Nancy, France | Completed | No outcome recorded |
| — | NCT02800135 | Apr 2016 → Mar 2018 | — | University Hospital of Saint-Etienne | Terminated | No outcome recorded |
| — | NCT02047422 | Jan 2014 → Feb 2016 | congestive heart failure | Yonsei University | Withdrawn | No outcome recorded |
| — | NCT01705470 | Oct 2012 → Jun 2013 | aregenerative anemia | Tel-Aviv Sourasky Medical Center | Withdrawn | No outcome recorded |
| — | NCT01709227 | Oct 2011 → Jun 2015 | acute kidney injury | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| — | NCT01275729 | Dec 2010 → Jun 2022 | acute kidney injury | University of Chicago | Completed | No outcome recorded |
| — | NCT01320007 | Sep 2010 → Oct 2014 | heart failure | Barts & The London NHS Trust | Completed | No outcome recorded |
| — | NCT01146288 | Jul 2010 → May 2014 | medulloadrenal hyperfunction | Rabin Medical Center | Completed | No outcome recorded |
| — | NCT01072071 | Feb 2010 → Dec 2011 | — | Ziekenhuis Netwerk Antwerpen (ZNA) | Unknown | No outcome recorded |
| — | NCT00962286 | Sep 2009 → May 2010 | medulloadrenal hyperfunction | Rabin Medical Center | Terminated | No outcome recorded |
| — | NCT00673244 | Apr 2008 → Dec 2013 | acute kidney injury | George Washington University | Completed | No outcome recorded |
| — | NCT00531908 | Sep 2007 → Dec 2009 | acromegaly | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT00429897 | Aug 2006 → Jul 2007 | hypertensive disorder | University of Cambridge | Unknown | No outcome recorded |
| — | NCT00285805 | Feb → Oct 2006 | — | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00240019 | Dec 2003 → Apr 2006 | diabetic kidney disease | Stanford University | Completed | No outcome recorded |
| — | NCT00141596 | Jul 2003 → Oct 2006 | hypertensive disorder | St George's, University of London | Terminated | No outcome recorded |
| — | NCT00175227 | May 1996 → Oct 2000 | acute kidney injury, chronic kidney disease | University of Alberta | Completed | No outcome recorded |
| — | NCT00246675 | — | cardio-renal syndrome | Melbourne Health | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 119 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02983422 Comparator | Dec 2016 → Jun 2017 | acute kidney injury | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | Unknown | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT06899061 Comparator | Mar 2025 → Feb 2026 overdue | high grade malignant neoplasm | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05470283 Background | Sep 2022 → Apr 2027 expected | metastatic melanoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03509545 Comparator | Jun 2021 → Jun 2022 | — | Sarfez Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04130815 Comparator | Oct 2019 → Sep 2020 | — | Oxford Brookes University | Unknown | No outcome recorded |
| Phase 1 | NCT03093090 Comparator | Dec 2018 → Jun 2019 | — | Yale University | Withdrawn | No outcome recorded |
| Phase 1 | NCT02646540 Comparator | Jan 2016 → Dec 2018 | cardiomyopathy, congestive heart failure | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT01558674 Comparator | May → Dec 2014 | heart failure, impaired renal function disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT00909519 Background | Jan → Apr 2009 | — | NicOx | Completed | No outcome recorded |
| Phase 1 | NCT00611741 Background | Mar 2007 → Mar 2011 | schizophrenia | Yale University | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT03180450 Background | Dec 2025 → Jun 2026 | heart failure | Sclnow Biotechnology Co., Ltd. | Suspended | No outcome recorded |
| Phase 1/2 | NCT03753204 Background | Sep 2021 → Sep 2026 expected | hypertensive disorder | Vanderbilt University Medical Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02356159 Background | Sep 2015 → Dec 2024 | Hodgkins lymphoma, acute leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT02575963 Background | Oct 2012 → Nov 2018 | acute myeloid leukemia | Actinium Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT01860170 Comparator | Apr 2012 → Mar 2016 | hematopoietic and lymphoid cell neoplasm | Corewell Health West | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06036914 Comparator | Nov 2023 → Oct 2024 | heart failure | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03901729 Comparator | May 2019 → Apr 2021 | heart failure | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT03730961 Background | Jan → Dec 2019 | congestive heart failure | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT04785755 Background | Nov 2017 → Mar 2020 | — | Hala Abd EL-Tawab Ibrahim Radwan | Completed | No outcome recorded |
| Phase 2 | NCT03136198 Background | Jul 2017 → Mar 2019 | heart failure, pulmonary edema | Indiana University | Completed | No outcome recorded |
| Phase 2 | NCT02312115 Comparator | Sep → Oct 2016 | — | Loma Linda University | Withdrawn | No outcome recorded |
| Phase 2 | NCT02501213 Comparator | May 2016 → Nov 2017 | cancer | Centre Oscar Lambret | Terminated | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT07469722 Comparator | Mar 2026 → Jan 2028 expected | congestive heart failure | Hospital de Clinicas de Porto Alegre | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05933642 Comparator | Jul → Dec 2023 | acute kidney injury | University of Malaya | Unknown | No outcome recorded |
| Phase 2/3 | NCT02173288 Background | Jul 2013 → Mar 2016 | cirrhosis of liver | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 2/3 | NCT00978354 Comparator | Sep 2009 → Jul 2014 | acute kidney injury | University of Alberta | Terminated | No outcome recorded |
| Phase 2/3 | NCT00953303 Comparator | Jan 2009 → Sep 2011 | heart failure | Hebei Medical University | Completed | No outcome recorded |
| Phase 318 trials | ||||||
| Phase 3 | NCT07596329 Background | Sep 2026 → Nov 2027 expected | chronic kidney disease, congestive heart failure | University of Monastir | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07223502 Comparator | Dec 2025 → Jul 2026 overdue | hypertensive disorder | Sarfez Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06898515 Comparator | Jul 2025 → Aug 2027 expected | heart failure | Reprieve Cardiovascular, Inc | Recruiting | No outcome recorded |
| Phase 3 | NCT05093621 Comparator | Feb 2021 → Jun 2023 | heart failure | Yale University | Completed | No outcome recorded |
| Phase 3 | NCT04533997 Background | Jan 2021 → May 2023 | heart failure | Puerta de Hierro University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05079789 Comparator | Jun 2020 → Nov 2022 | nephrotic syndrome | University Hospital Tuebingen | Terminated | No outcome recorded |
| Phase 3 | NCT03296813 Comparator | Jul 2018 → Jul 2022 | heart failure | Duke University | Completed | No outcome recorded |
| Phase 3 | NCT04628325 Background | Mar 2017 → Jun 2019 | congestive heart failure | University of Palermo | Completed | No outcome recorded |
| Phase 3 | NCT02689180 Comparator | May 2015 → May 2017 | heart failure | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 3 | NCT02268903 Comparator | Apr 2015 → Apr 2018 | pulmonary embolism | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 3 | NCT03592836 Comparator | May 2013 → Dec 2017 | advanced heart failure, moderate heart failure | University of Turin, Italy | Completed | No outcome recorded |
| Phase 3 | NCT01628731 Comparator | Oct 2012 → Jul 2013 | — | Bambino Gesù Hospital and Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT01290146 Comparator | Feb 2011 → Jun 2015 | advanced heart failure | Niguarda Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT01210365 Comparator | Jan 2011 → Mar 2013 | congestive heart failure | Eurofarma Laboratorios S.A. | Terminated | No outcome recorded |
| Phase 3 | NCT00372762 Comparator | Jan 2011 → Jan 2013 | heart failure | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Withdrawn | No outcome recorded |
| Phase 3 | NCT00936923 Comparator | Jun 2008 → Dec 2011 | impaired renal function disease | Sun Yat-sen University | Withdrawn | No outcome recorded |
| Phase 3 | NCT00151827 Background | Aug 2003 → Jul 2005 | essential hypertension, impaired renal function disease | Sankyo Pharma Gmbh | Completed | No outcome recorded |
| Phase 3 | NCT00000620 Background | Sep 1999 → Jun 2009 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 438 trials | ||||||
| Phase 4 | NCT07593612 Background | Jun 2026 → Jan 2027 expected | heart failure | Lucrecia Maria Burgos | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07263035 Comparator | Apr 2026 → Jun 2027 expected | heart failure | Lakeland Regional Health Systems, Inc. | Recruiting | No outcome recorded |
| Phase 4 | NCT07076615 Background | Aug 2025 → May 2026 overdue | heart failure | May Mohamed Abdalla | Recruiting | No outcome recorded |
| Phase 4 | NCT06414759 Background | Jul → Dec 2024 overdue | heart failure | Cairo University | Recruiting | No outcome recorded |
| Phase 4 | NCT06442280 Comparator | Jun 2024 → Jan 2026 | symptomatic heart failure, type 2 diabetes mellitus | University of Palermo | Unknown | No outcome recorded |
| Phase 4 | NCT06203236 Comparator | Jan 2024 → Mar 2025 | chronic kidney disease, heart failure | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT05986773 Comparator | Oct 2023 → Dec 2024 | heart failure | Stadtspital Zürich | Terminated | No outcome recorded |
| Phase 4 | NCT05276219 Comparator | Sep 2023 → May 2027 expected | congestive heart failure, pulmonary edema | Rigshospitalet, Denmark | Recruiting | No outcome recorded |
| Phase 4 | NCT05904808 Comparator | Apr → Aug 2023 | congestive heart failure | Rambam Health Care Campus | Completed | No outcome recorded |
| Phase 4 | NCT06218199 Comparator | Jul 2021 → Dec 2025 overdue | congestive heart failure | Heart Center Research, LLC | Recruiting | No outcome recorded |
| Phase 4 | NCT04180397 Comparator | Aug 2020 → Apr 2027 expected | — | Morten H. Bestle | Recruiting | No outcome recorded |
| Phase 4 | NCT04216784 Comparator | Dec 2019 → Dec 2023 | cirrhosis of liver | Rush University Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT04062760 Comparator | Dec 2019 → Dec 2021 | heart failure | University of Parma | Unknown | No outcome recorded |
| Phase 4 | NCT03746002 Comparator | Jan 2019 → Jan 2020 | heart failure | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 4 | NCT02767024 Background | May 2018 | symptomatic heart failure | Montefiore Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT03226457 Comparator | Dec 2017 → Dec 2018 | heart failure, type 2 diabetes mellitus | University of Dundee | Completed | No outcome recorded |
| Phase 4 | NCT01815892 Comparator | May 2015 → Dec 2016 | end stage renal failure | Unity Health Toronto | Unknown | No outcome recorded |
| Phase 4 | NCT02427880 Comparator | Apr → Jun 2015 | nephrotic syndrome | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02183792 Comparator | Dec 2014 → Feb 2018 | heart failure | University of Southern California | Completed | No outcome recorded |
| Phase 4 | NCT05840536 Background | May 2014 → Oct 2015 | heart failure | Ochsner Health System | Withdrawn | No outcome recorded |
| Phase 4 | NCT01945801 Comparator | Oct 2013 → Feb 2015 | obstructive sleep apnea syndrome | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 4 | NCT01942109 Comparator | Sep 2013 → Dec 2017 | heart failure | Medical University of Warsaw | Unknown | No outcome recorded |
| Phase 4 | NCT01901809 Comparator | Aug 2013 → Jun 2017 | diastolic heart failure | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT01863511 Comparator | May 2013 → Dec 2015 | heart failure | The Christ Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01588795 Comparator | Apr 2012 → Jan 2016 | diabetic kidney disease, proteinuria | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT01549158 Comparator | Feb → Oct 2012 | heart failure | Ferrer Internacional S.A. | Terminated | No outcome recorded |
| Phase 4 | NCT01419132 Comparator | Aug → Sep 2011 | symptomatic heart failure | University of Palermo | Completed | No outcome recorded |
| Phase 4 | NCT01288794 Comparator | Mar 2011 → Nov 2014 | cirrhosis of liver | University of Bologna | Completed | No outcome recorded |
| Phase 4 | NCT01140399 Comparator | Feb → Jun 2011 | heart failure | Niguarda Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01073189 Comparator | Apr 2010 → Jan 2011 | acute kidney injury | Southeast Renal Research Institute | Withdrawn | No outcome recorded |
| Phase 4 | NCT01060293 Comparator | Jul 2009 → Dec 2013 | heart failure | Larissa University Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00937092 Comparator | Jan 2009 → Jan 2010 | heart failure | Larissa University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00904488 Comparator | Oct 2008 → May 2016 | heart failure | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 4 | NCT00409942 Comparator | Mar 2007 → Jun 2009 | congestive heart failure | Ferrer Internacional S.A. | Completed | No outcome recorded |
| Phase 4 | NCT00439075 Comparator | Oct 2006 → Apr 2008 | pulmonary edema | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 4 | NCT00355667 Comparator | Jun 2006 → Aug 2010 | congestive heart failure | Hyogo Medical University | Completed | No outcome recorded |
| Phase 4 | NCT00421863 Background | Feb 2005 → Jan 2009 | hypertensive disorder | Heart Care Foundation | Completed | No outcome recorded |
| Phase 4 | NCT00663195 Background | Jan 2004 → Dec 2005 | heart failure | Tottori University Hospital | Completed | No outcome recorded |
| Phase not applicable36 trials | ||||||
| — | NCT07568574 Background | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
| — | NCT07286409 Comparator | Jan → Dec 2026 expected | acute respiratory distress syndrome | Tanta University | Not yet recruiting | No outcome recorded |
| — | NCT07335900 Background | Dec 2025 → Dec 2026 expected | aortic valve stenosis | RenJi Hospital | Recruiting | No outcome recorded |
| — | NCT06786728 Comparator | Aug 2024 → Jul 2025 overdue | cardio-renal syndrome | Benha University | Enrolling by invitation | No outcome recorded |
| — | NCT06362668 Comparator | May → Oct 2024 | heart failure | Reprieve Cardiovascular, Inc | Completed | No outcome recorded |
| — | NCT06273397 Background | May 2024 → Mar 2027 expected | symptomatic heart failure | Clinica Alemana de Santiago | Not yet recruiting | No outcome recorded |
| — | NCT05599971 Comparator | Feb → Nov 2023 | plantar wart | Zagazig University | Unknown | No outcome recorded |
| — | NCT06467825 Background | Aug 2022 → Sep 2025 overdue | — | National Aeronautics and Space Administration (NASA) | Recruiting | No outcome recorded |
| — | NCT05520658 Comparator | Jul → Sep 2022 | plantar wart | Sohag University | Unknown | No outcome recorded |
| — | NCT05129358 Background | May 2022 → Nov 2023 | — | Mode Sensors AS | Completed | No outcome recorded |
| — | NCT05287100 Background | Jan 2022 → May 2023 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT04572867 Comparator | Jun → Jul 2021 | congestive heart failure, symptomatic heart failure | Ramona Gelzer Bell | Withdrawn | No outcome recorded |
| — | NCT04893629 Comparator | May 2021 → Nov 2024 | cardiomyopathy | Damascus University | Terminated | No outcome recorded |
| — | NCT05569655 Background | Apr 2021 → Nov 2022 | pulmonary arterial hypertension | Chinese Pulmonary Vascular Disease Research Group | Unknown | No outcome recorded |
| — | NCT04219150 Background | Jan 2020 → Feb 2021 | acute respiratory distress syndrome | Tanta University | Completed | No outcome recorded |
| — | NCT03750136 Background | Dec 2018 → Jan 2023 | nephrotic syndrome | Medical University of Bialystok | Unknown | No outcome recorded |
| — | NCT03645642 Background | Sep → Dec 2018 | hepatobiliary disorder | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT05298098 Comparator | Jul 2018 → Sep 2023 | heart failure | University of Monastir | Unknown | No outcome recorded |
| — | NCT02649998 Comparator | Jan 2017 → Dec 2021 | heart failure | Chinese University of Hong Kong | Withdrawn | No outcome recorded |
| — | NCT03082742 Comparator | Aug 2015 → Jun 2018 | chronic kidney disease, secondary hyperparathyroidism of renal origin | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| — | NCT03547895 Comparator | Jun 2015 → May 2016 | cirrhosis of liver | Zagazig University | Completed | No outcome recorded |
| — | NCT02712476 Comparator | Jul 2013 → May 2015 | brain neoplasm | Istanbul University | Completed | No outcome recorded |
| — | NCT02068937 Comparator | May 2013 → Dec 2017 | heart failure | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| — | NCT01817803 Comparator | Mar 2013 → Jun 2015 | congestive heart failure | Yonsei University | Withdrawn | No outcome recorded |
| — | NCT01508260 Comparator | Mar 2013 → Mar 2018 | leukemia | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| — | NCT02372292 Comparator | Feb 2013 → Jun 2015 | cardio-renal syndrome | Ankara University | Completed | No outcome recorded |
| — | NCT01584518 Comparator | Jul 2012 → Jun 2013 | — | Creighton University | Completed | No outcome recorded |
| — | NCT01617798 Comparator | Jun 2012 → Jun 2013 | respiratory failure | Oregon Health and Science University | Withdrawn | No outcome recorded |
| — | NCT01474200 Comparator | Jan 2012 → Jul 2014 | heart failure | Nuwellis, Inc. | Terminated | No outcome recorded |
| — | NCT01457053 Comparator | Nov 2011 → May 2013 | heart failure | University of Cincinnati | Terminated | No outcome recorded |
| — | NCT01318967 Comparator | Oct 2010 → Jun 2012 | chronic kidney disease | Wake Forest University | Completed | No outcome recorded |
| — | NCT01054404 Comparator | Feb 2010 → Mar 2012 | brain edema, dehydration polycythemia | Northwestern University | Terminated | No outcome recorded |
| — | NCT00924014 Comparator | Jul → Dec 2009 | heart failure | Hennepin County Medical Center, Minneapolis | Unknown | No outcome recorded |
| — | NCT00690521 Background | Oct 2004 → Nov 2009 | congestive heart failure | University of New Mexico | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT01852669 Background | Jan 2002 → Dec 2008 | urolithiasis | Monash University | Completed | No outcome recorded |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 299 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FUROSEMIDE | “The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide,...” NCT04192110 ↗286“A Phase 2, Randomized, Vehicle-controlled, Double-blind Study to Explore the Efficacy, Pharmacodynamics and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of...” NCT03334240 ↗ “Patients were randomized to receive either usual care, including conventional optimal treatment with furosemide, oxygen, and high-dose boluses of isosorbide dinitrate plus...” PMID 20825901 ↗ May 2010 “Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the...” NCT01588795 ↗ “Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered...” NCT04593823 ↗ “Furoscix (furosemide injection 8 mg/ml), is a furosemide solution buffered to a neutral pH containing 80 mg/10 mL for subcutaneous administration over 5 hours via the Furoscix Infusor.” NCT03458325 ↗ “Lung ultrasound guided therapy; if pulmonary congestion (more or equal than 3 B-lines), high dose (80-120mg PO/day furosemide) will be prescribed until next follow up re-assessment.” NCT03613779 ↗ “In cases where the patient was not previously on oral diuretics, a starting dose of 40 mg of IV furosemide, IV bumetanide 1 mg or a bolus of 20 mg of IV torsemide can be utilized.” NCT06414759 ↗ “Furosemide: Nebulized furosemide has been studied as a potential treatment option for ARDS patients due to its diuretic properties and potential to reduce pulmonary edema.” NCT07286409 ↗ “including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.” NCT03180450 ↗ “The patients in this arm will be randomized to receiving oral furosemide in 2 daily divided doses at twice the intravenous dose administered during the past 24 hours.” NCT04062760 ↗ “Treatment in the UC and UC+T arms will begin with a furosemide bolus(double the home dose or if unavailable, 60mg) and continue with a drip(10 or 20 mg/hr).” NCT01863511 ↗ “Patients receive intravenous infusion of HSS (50ml of 10% NaCl) + Furosemide ( 250mg of furosemide) administered over one hour twice a day.” NCT05298098 ↗ “Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio)” NCT04785755 ↗ “Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h” NCT01290146 ↗ “A novel pH-neutral formulation of SC furosemide containing 80 mg furosemide in ∼2.7 mL (infused over 5 h) was investigated.” PMID 37804170 ↗ Jan 2024 “If a patient with overhydrated status indicated by the ECW ratio was more than 0.406, 10mg of furosemide was administered.” NCT06097923 ↗ “furosemide 100mg for one month;furosemide 200mg for one month;furosemide 100mg and hydrochlorothiazide 25mg for one month;” NCT04182854 ↗ “The proposed study aims to compare the pharmacokinetics and bioavailability of intravenous and subcutaneous Furosemide.” NCT02329834 ↗ “Initial dose of intravenous furosemide ≤80 mg / day regardless of prior dose of loop diuretics who were receiving.” NCT02643147 ↗ “IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive.” NCT03136198 ↗ “Subcutaneous Injection of SCP-111 (Furosemide) vs Intravenous Injection of Furosemide in Healthy Volunteers” NCT06167707 ↗ “Patients were assigned in a 1:1 ratio to receive furosemide by bolus every 12 h or by continuous infusion.” PMID 31256261 ↗ Jun 2019 “Treatment will be up to 80 mg furosemide or equivalent doses of other loop diuretics and 10 mg finerenone” NCT07223502 ↗ “IV furosemide (unless already given) (All patients receive at minimum 20 mg IV furosemide or equivalent)” NCT03259165 ↗ “Furosemide 5 mg is given intravenously over 2 hours until approximately 2 liters of body fluid is lost.” NCT01062776 ↗ “This includes furosemide or other IV loop diuretics administered at equivalent doses to furosemide.” NCT01474200 ↗ “Study Drug: Furoscix®, (Furosemide Injection), 80 mg/10 mL is a proprietary furosemide formulation” NCT05528588 ↗ “Standard Medical therapy (n-15) with100 to 400mg spironolactone and/or 40 to 160mg furosemide.” NCT02173288 ↗ “Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.” NCT03645642 ↗ “Standard care intravenous loop diuretics (e.g., furosemide) according to clinical protocol” NCT07076615 ↗ “40 mg of nebulized furosemide in 4 mL of saline nebulized over 30 minutes every 6 hours” NCT05440851 ↗ “loop-acting diuretic (furosemide,0.5- 2 mg/kg per day) was given with dose escalation” NCT05287100 ↗ “treated with anti-aldosteronic drugs (≥200 mg/day) and furosemide (≥25 mg/day)” PMID 29861076 ↗ Jun 2018 “Furosemide on as needed basis to maintain fluid balance is also given.” NCT01860170 ↗ “Digoxin 0.25 mg, furosemide 1 mg, metformin 10 mg, rosuvastatin 10 mg” NCT04233437 ↗ “metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene” NCT00684489 ↗ “Furosemide (FUROSEMIDE®) 20 mg / 2ml, ampoule for injection” NCT03731117 ↗ “combined spironolactone 100 mg plus furosemide 20 mg daily” PMID 25906818 ↗ Apr 2015 “Furosemide; torsemide; nitroglycerin; dopamine; Dobutamine” NCT00953303 ↗ “through intravenous injection of up to 40 ug Furosemide” NCT05129358 ↗ “Diurisa® (furosemide 40 mg + amiloride chloride 10 mg)” NCT01210365 ↗ “Providing subcutaneous furosemide to eligible patients” NCT06979726 ↗ “Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3” NCT02356159 ↗ “furosemide 40 mg/d if eGFR is \< 30 mL/min/1.73m²” NCT02539810 ↗ “loop diuretics such as furosemide and torasemide” NCT07335900 ↗ “Furosemide Topical Gel 0.125% (CLS006)” NCT03259620 ↗ “Furosemide topical formulation” NCT02333643 ↗ “furosemide administration” NCT04219150 ↗ “furosemide (Lasix) 40mg” NCT06710600 ↗ “Furosemide Topical Gel” NCT03684772 ↗ “Lasix (Furosemide)” NCT02646540 ↗ “furosemide” NCT00000620 ↗ “furosemide” NCT00000620 ↗ “furosemide” NCT02765009 ↗ |
| Known as | CLS006 | “Furosemide Topical Gel 0.125% (CLS006)” NCT03259620 ↗1“CLS006 (Furosemide) Topical Gel” NCT02971891 ↗ |
| Known as | frusemide | “Hydration of patient with 0.5L NaCl and 20mg frusemide IV” NCT01852669 ↗ |
| Known as | Furoscix | “The study drug, Furoscix (furosemide injection 8 mg/ml), is a furosemide solution buffered to a neutral pH containing 80 mg/10 mL for subcutaneous administration over 5 hours...” NCT04593823 ↗3“The study drug, Furoscix (furosemide injection 8 mg/ml), is a furosemide solution buffered to a neutral pH containing 80 mg/10 mL for subcutaneous administration over 5 hours...” NCT03458325 ↗ “Study Drug: Furoscix®, (Furosemide Injection), 80 mg/10 mL is a proprietary furosemide formulation” NCT05528588 ↗ “Furoscix 80 mg will be administered as a subcutaneous infusion.” NCT04161482 ↗ |
| Known as | Furosemide Injection | “Study Drug: Furoscix®, (Furosemide Injection), 80 mg/10 mL is a proprietary furosemide formulation” NCT05528588 ↗ |
| Known as | Furosemide Injection Solution | “The test formulation in this study is a buffered solution, Furosemide Injection Solution at 8 mg/mL at pH 7.4 (range 7.0 to 7.8) and is intended for SC injection according to...” NCT02329834 ↗ |
| Known as | Furosemide Injection Solution (SCP-101) | “Patients will be randomized to receive Furosemide Injection, USP intravenously or Furosemide Injection Solution (SCP-101) delivered subcutaneously.” NCT02579057 ↗ |
| Known as | Furosemide Injection, USP | “Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.” NCT02329834 ↗ |
| Known as | Furosemide USP | “Drug: Furosemide USP” NCT06167707 ↗ |
| Known as | Furosemide: Seguril | “Furosemide: Seguril” NCT00409942 ↗ |
| Known as | HOE058 | “Drug: FUROSEMIDE (HOE058)” NCT01724788 ↗ |
| Known as | Lasix | “Furosemide (Lasix) is frequently administered to patients with acutely decompensated heart failure to relieve pulmonary vascular congestion and promote diuresis.” NCT00652652 ↗10“Furosemide (Lasix, 20 mg) will be administered through IV catheter to induce urination.” NCT06467825 ↗ “Cohort 1 will receive furosemide (Lasix) 40 to 80 mg IVP BID for at least 48 hours” NCT04216784 ↗ “Placebo Comparator: Control-- furosemide (lasix) only” NCT01617798 ↗ “the other one will receive furosemide 40 mg (Lasix®)” NCT01210365 ↗ “Intervention: drug: furosemide ; other name: lasix” NCT02821377 ↗ “to a maximum of 8mg IV Bumex (or 320mg IV Lasix).” NCT04572867 ↗ “Furosemide (Lasix), 20 milligram, PO, PO, daily” NCT03556761 ↗ “furosemide (Lasix) 40mg” NCT06710600 ↗ |
| Known as | Lasix (Furosemide) | “Lasix (Furosemide)” NCT02646540 ↗1“Lasix, furosemide” NCT01457053 ↗ |
| Known as | Lasix (Sanofi-Aventis) | “Lasix (Sanofi-Aventis)” NCT01072071 ↗ |
| Known as | Lasix ONYU | “The investigators will conduct an open-label, non-comparative, real-world study to evaluate the effectiveness and feasibility of at-home decongestion treatment using Lasix ONYU...” NCT06979726 ↗1“prefilled units of Lasix® ONYU furosemide injection containing 80 mg per 2.67 mL” NCT07018297 ↗ |
| Known as | SCP-111 | “Subcutaneous Injection of SCP-111 (Furosemide) vs Intravenous Injection of Furosemide in Healthy Volunteers” NCT06167707 ↗ |
| Known as | SQINFurosemide | “SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.” NCT04846816 ↗1“SQIN-Furosemide is a novel formulation of furosemide at 30mg/mL at pH 7.5 (range 7.1 to 7.8) intended for subcutaneous use.” NCT07269496 ↗ |
| Action | Inhibit | “25 mg furosemide (a Na-K-2Cl cotransporter blocker)” PMID 21508131 ↗ Apr 2011 |
| Modality | Other / unclassified | “two standard of care loop diuretics (furosemide versus torsemide)” NCT05093621 ↗ |
| Route | Oral | “Furosemide oral tablets” NCT00151827 ↗ |